Metropolis Healthcare Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Strong Q1 with 23% total revenue growth: Organic growth hit 13.2%, driven by volume and improved realizations, while acquisitions added scale. The quarter was seasonally soft in some regions but still delivered broad-based recovery.
• Core Diagnostics turned EBITDA-positive: The acquisition moved from break-even in Q4 to low single-digit EBITDA margin, with a clear path to high single-digits by year-end through cost synergies and lab consolidation.
• B2C momentum is the core engine: Organic B2C revenue grew 16% YoY on 9% volume and 6% mix/pricing, with preventive health now 18% of the portfolio and Tier-3 towns showing strong patient volume growth.
• Margins set to expand every quarter: Organic EBITDA margin at 24.7% improved over Q4, and management expects a YoY uptrend each quarter this year as lab expansion benefits begin flowing and acquisition synergies kick in.
• What to watch next quarter: Whether Core Diagnostics reaches high single-digit EBITDA margin, the pace of B2C share migration toward the 60%+ target, and any decision on entering high-end radiology.

Revenue Growth & Drivers

• Organic growth engine: 13.2% organic revenue growth came from patient volumes and improved realizations, supported by brand equity and specialty diagnostic expertise. The recovery was broad-based after a temporary dip in Q4 last year due to seasonal and regional factors.
• B2C performance: Organic B2C revenue grew 16% YoY, split between 9% patient volume growth and 6% from improved test mix and pricing. Maharashtra B2C also grew 16% with Mumbai outperforming the state average due to deeper brand equity and broader test offerings.
• B2B performance: B2B revenue grew 10% YoY with 4% patient volume growth and 6% RPP increase, driven primarily by high-value outsourcing from hospitals and increased pharmaceutical partnerships.
• Preventive health: TruHealth now contributes 18% of the portfolio, integrating blood diagnostics, non-blood vital checks, and doctor consultation. It is a key driver of footfall and volume growth across urban and rural markets.
• Specialty test growth: High-end specialty tests in oncology and genomics are adding both volume and value with higher RPP, reinforcing the company's science-led positioning.
• Network expansion: Geographic expansion into underserved Tier-3 and peri-urban markets through the hub-and-spoke model is showing strong patient volume growth, driven by brand preference, wider test menu, and improved local infrastructure. The company aims to expand from ~750 towns to 1,000 towns.
• Digital enablement: Increased adoption of the Metropolis app with personalized health journeys, real-time tracking, and end-to-end digital integration improved customer satisfaction and operational efficiency by reducing manual dependency and lowering turnaround times.
• Government contract exit: The company concluded its engagement with Aam Aadmi Mohalla Clinics effective June 30, in line with its strategy to move away from low-margin government contracts and focus on higher-margin B2C and B2B segments.

Shah: "It is a big year for us that we believe we are going to take a big leap forward, not only in breaking our own record for organic growth that we have seen, but also significantly improving on the margin, but really integrating the three acquisitions and making them really part of Metropolis and setting the stage for them to accelerate in the years to come."

Margin Trajectory & Productivity

• Organic margin improvement: Organic EBITDA margin reached 24.7%, higher than Q4 last year. Group EBITDA was marginally impacted by Core Diagnostics consolidation at low single-digit margins.
• Productivity initiatives: Automation and digital workflows are now live and starting to contribute to productivity. Lab infrastructure expansion concluded last quarter, shifting focus to scaling the collection center network to drive higher throughput and utilization.
• Lab expansion margin drag ending: New labs typically run at negative margin in year one, positive 10-12% in year two, and reach company levels in year three. The full benefit of halted lab expansion, estimated at 1% plus, will be realized by end of FY27.
• Gross margin drivers: Price stability is becoming more predictable, operational efficiencies from automation and digitization are flowing through, and scale is improving profitability.
• Quarterly margin uptrend: Management expects to strengthen EBITDA margin every quarter this year on a YoY basis, with expansion starting from Q2 itself.
• Collection center expansion: The company is on track to add approximately 400-plus collection centers this year, with strong focus on Tier-2 and Tier-3 towns, which will drive higher throughput and utilization for better margins over time.

Surendran: "First year, it normally gets into a negative margin and the year two, it gets into a positive 10-12% margin and the year three normally gets into the Company levels of margin."

Acquisitions & Integration

• Core Diagnostics turnaround: Core showed positive YoY revenue growth and improved from break-even in Q4 FY25 to low single-digit EBITDA margin in Q1. PAT remained negative due to high depreciation and high-cost interest on a ₹12 crores loan, which was refinanced in July at a better rate.
• Core margin path: Management expects Core to reach high single-digit EBITDA margin by end of FY26, driven primarily by cost synergies rather than revenue mix. Five overlapping labs where Metropolis and Core both had facilities were merged in Q1. Over the next 3-4 years, Core can reach company-level margins, with revenue acceleration kicking in by year two.
• Core was structurally unprofitable standalone: Core was subscale with corporate and lab costs that would never have allowed it to be profitable on its own. Integration into Metropolis unlocks the cost structure that makes profitability possible.
• Three acquisitions integrated: Scientific Pathology, DAPIC, and Core Diagnostics integrations are progressing smoothly with no significant challenges. Synergies are already yielding in lab consolidation, procurement efficiencies, and overhead reduction.
• Two-year integration plan: Year one focuses on full integration, operational efficiency, and margin improvement. Year two shifts to accelerating revenue growth through cross-selling and expanding reach across the pan-India network.
• Ambika Diagnostics acquisition: Acquired for ₹17 crores, this was a lease-owned lab run by Metropolis for two years. Post-acquisition, it will be merged with Metropolis's existing Kolhapur lab to create the largest lab in the region. Management noted that while the headline multiple looks like 9.4x FY25 EBITDA, post-synergy EBITDA of ₹3.4 crores implies an effective 5x multiple. The acquisition is expected to be highly accretive from day one.
• Future acquisitions: No imminent acquisitions expected in the next quarter or so. The company continues to evaluate funnels of different sizes but only if they fit culture, strategy, and create shareholder value.

Shah: "Core was a good business on its own, but the chances of it making money on its own profitably was low because it was subscale, and the kind of corporate costs that were involved and the kind of lab costs that were involved would never have allowed it to make money on its own."

B2C/B2B Mix & Segment Strategy

• Segment reclassification: The institutional bucket was dropped this quarter. B2C now includes company-owned centers, franchisee centers, and rural collection centers. B2B includes service to labs, hospitals, government, corporates, and pharma.
• Group B2C share: Group B2C stands at 56%, lower than organic 59%, because Core Diagnostics has a majority B2B revenue mix. The first target is to move group B2C to 60%+ levels.
• Core B2C expansion: Cross-selling specialty tests across the Metropolis network and leveraging existing channels is expected to increase Core's B2C share over time.
• Tier-3 unit economics: Expansion into Tier-3 towns is done through the franchisee route for centers only, not labs. Metropolis investments are in clinician engagement and logistics, which are already stitched. Unit economics are at par with other Tier-3 towns and improve as volumes increase from deeper penetration.
• RPP trend: Realization per patient has historically increased 3-5% per year, driven more by moving up the value chain and selling specialized tests than by pricing. Management expects past five-year trends to sustain, but doubling RPP over five years would require 15-20% annual increases, which is unlikely.

New Initiatives & Competitive Landscape

• Basic radiology pilot: Currently in 20 locations offering full radiology (X-ray, sonography, ECG), 36 locations offering X-ray, and 240 locations offering ECG. These are added to existing centers with no extra cost other than processing, so margins should be at par or better. Revenue contribution is not expected to be significant unless the company enters high-end radiology.
• High-end radiology decision pending: Management is evaluating whether higher-end radiology is worth entering, with a clearer direction expected over the next couple of quarters.
• Oncology Center of Excellence: Under construction, it will centralize genomics, histopathology, cytogenetics, molecular oncology, and precision testing, serving as a hub for clinical collaboration, research, and education. Combined with Core Diagnostics, this creates a platform to become the largest oncology testing player in India.
• AI in diagnostics: Management sees no player in India using AI in a scaled or differentiated way that is severely disruptive to the existing industry. If a scaled use case for Point of Care diagnostics emerges, Metropolis would consider using that channel to access new customers or markets.
• Competitive intensity moderating: The 2020-2023 period saw a black swan event that attracted new corporate and health-tech players. As some players realize the industry is not for them, funding has slowed or become a "funding winter" because unit economics have not been proven. Pricing is now more rational, though players remain in the market.

Shah: "The organic growth in the industry is about 8% to 10%. And anything you want to do above that, or even to reach there, is going to take a lot of hard work and a lot of patience and long term vision."

Volume & Pricing Dynamics

• Volume growth guidance: Organic business patient volume is expected to continue at the 7% level and improve going forward. Group-level volume growth of 10-11% is expected for this year.
• B2C volume and mix: The 16% B2C revenue growth comprised 9% patient volume growth and 6% from improved test mix and pricing, reflecting differentiated, value-add diagnostics.
• B2B volume and RPP: B2B patient volume grew 4% while RPP rose 6%, driven primarily by high-value outsourcing from hospitals.
• Management declined to provide separate patient volume and revenue growth for Core Diagnostics on a YoY basis, citing that it is too early in the acquisition to disclose separate growth and margin details.
• Management also declined to provide absolute volume numbers for B2C and B2B, or average revenue per test splits, though they noted a difference of approximately 20% or more between the two segments.

Guidance & Commitments

Key Metrics